Correction: Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study

Shen L, Guo J, Zhang Q, et al. Tislelizumab in Chinese patients with advanced solid tumors: an open-label, non-comparative, phase 1/2 study. J immunother Cancer 2020;8:e000437. doi: 10.1136/jitc-2019-000437

Since the online publication of this article, the authors have noticed that the author name Zuobai Wang was incorrectly spelt as Zoubai Wang. This has been corrected.